Numerous studies have confirmed that CD155 overexpression in tumors serves not only as a direct indicator of tumor progression but is also closely correlated with poor prognosis in patients (Qu et al., 2015; Xu et al., 2020; Hai et al., 2020). Here, PVR is linked to neoplasm.